Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

iShares U.S. Pharmaceutical ETF (NY: IHE )

65.71 +0.56 (+0.86%)
Official Closing Price Updated: 8:00 PM EST, Dec 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 53,190
Open 65.88
Bid (Size) 62.16 (32)
Ask (Size) 66.90 (30)
Prev. Close 65.15
Today's Range 65.58 - 66.47
52wk Range 60.60 - 72.94
Shares Outstanding 91,500
Dividend Yield 2.19%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Your Healthcare Costs are Soaring! US Spending Reached $5 Trillion In 2023 with Major Increase in Obesity and Diabetes Drugs, Hospital Services
U.S. healthcare spending grew 7.5% to $4.9 trillion in 2023, with hospital care and prescription drugs driving costs. Private insurance accounted for 30% of total spending. 
Via Benzinga
Eli Lilly Stock Soars 34.42% YTD: A $1000 Investment Outpaces Returns From These ETFs Holding Mounjaro-Maker Shares
Recently, the company announced a massive $15 billion share buyback plan and a 15% dividend increase. 
Via Benzinga
Topics ETFs

Performance

YTD
+4.99%
+4.99%
1 Month
-3.45%
-3.45%
3 Month
-7.92%
-7.92%
6 Month
-2.51%
-2.51%
1 Year
+7.77%
+7.77%

More News

Read More
FDA Commissioner Califf Candid on Trump's Impact: 'We Just Don't Know What's Going to Happen'
Via Benzinga
Topics Government
Exposures Political Product Safety
3 Sector ETFs That Beat The Market Last Week
Via Talk Markets
Topics ETFs
US Pharmaceuticals: A Bifurcated Market
Via Talk Markets
Trump Has Asked Me To Do 3 Things, Says Robert Kennedy Jr.
Via Benzinga
Topics Government
Exposures Political
A Look At Pharma ETFs Post Q1 Earnings
Via Talk Markets
Topics ETFs
ETFs To Buy As Eli Lilly Beats Q1 Earnings, Lifts Outlook
Via Talk Markets
Topics ETFs
Eli Lilly, Novo Nordisk's Strategies Against New Weight-Loss Drug Competitors
Via Benzinga
A Look At Pharma ETFs After Q4 Earnings
Via Talk Markets
Topics ETFs
April Showers On Wall Street: Miners, Utilities Emerge As Bright Spots In Gloomy Market
Via Benzinga
Topics Stocks
Exposures US Equities
Bank Of America Predicts 10 2024 Market Surprises: From Booming IPOs To Japanese Equity Surge
Via Benzinga
Topics Bonds
Exposures Debt Markets
3 Beaten-Down ETFs To Buy For A Turnaround In 2024
Via Talk Markets
Topics ETFs
Exposures COVID-19
5 Secret Santa ETFs That Might Surprise You This Christmas
Via Talk Markets
Topics ETFs
Pharmacy Workers Strike At CVS and Walgreens, Echoing Wider Pharma Sector Unrest
Via Benzinga
5 Sector ETFs That Outperformed in Turbulent August
Via Talk Markets
Topics ETFs
Q2 Earnings & Market Sell-Off Impact: 5 Must-See ETF Charts
Via Talk Markets
Topics ETFs
Pharma ETFs in Focus Post Q2 Earnings
Via Talk Markets
Topics ETFs
3 Biotech Stocks to Sell in June Before They Crash and Burn
Via InvestorPlace
Pharma ETFs Gain Post Q1 Earnings
Via Talk Markets
A Look At Pharma ETFs Post Q4 Earnings
Via Talk Markets
4 Sector ETFs To Watch Ahead Of Mid-Election Results
Via Talk Markets
5 ETFs To Watch After 2022 Midterm Elections: Which Sectors Win From Republican Or Democrat Majority?
Via Benzinga
Pharma ETFs In Focus Post Q3 Earnings
Via Talk Markets
ETF Mid-Year Outlook & Investing Strategies
Via Talk Markets
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.